UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: applying pharmacokinetics to optimise dosing of anti‐TNF biologics in acute severe ulcerative colitis

Alimentary pharmacology & therapeutics, 2015-06, Vol.41 (11), p.1094-1103

2015

Volltextzugriff (PDF)

iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis

Patient education and counseling, 2022-06, Vol.105 (6), p.1628-1633

2022

Volltextzugriff (PDF)

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

Alimentary pharmacology & therapeutics, 2015-07, Vol.42 (2), p.241-241

2015

Volltextzugriff (PDF)

Uniaxial Compression Tests of Metallic Foams: A Recipe

Key engineering materials, 2014-03, Vol.601, p.237-241

2014

Volltextzugriff (PDF)

347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-59-S-59

2023

Volltextzugriff (PDF)

748 EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-177-S-178

2024

Volltextzugriff (PDF)

Tu1653: MODEL-INFORMED PRECISION DOSING WITH A PK DASHBOARD IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1023

2022

Volltextzugriff (PDF)

Su1884 ACUTE PANCREATITIS IS ASSOCIATED WITH GUT DYSBIOSIS IN CHILDREN

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-703-S-703

2023

Volltextzugriff (PDF)

Su1013 EVALUATION OF INSURANCE TYPE ON PRIOR AUTHORIZATION (PA) DELAYS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS PRESCRIBED BIOLOGIC THERAPIES

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-504-S-505

2023

Volltextzugriff (PDF)

Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-967-S-968

2020

Volltextzugriff (PDF)

DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S127-S127

2020

Volltextzugriff (PDF)

958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-226-S-227

2024

Volltextzugriff (PDF)

Su1585: BIOMARKERS OF DRUG CLEARANCE IN PEDIATRIC IBD – A REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-641-S-641

2022

Volltextzugriff (PDF)

525: EVALUATION OF HEALTH INEQUITIES IN PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-122-S-122

2022

Volltextzugriff (PDF)

Sa1762 – Large-Scale Proteomics Identifies Anti-TNF Response Signature

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-392-S-392

2019

Volltextzugriff (PDF)

Su1800 – Effect of Addition of an Immunomodulator on Outcomes in Pediatric Patients with Inflammatory Bowel Disease on Antitnf Monotherapy with New Anti-Drug Antibodies

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-617-S-617

2019

Volltextzugriff (PDF)

Su1792 – Elevation of Plasma Oncostatin M is Associated with Primary Biochemical Nonresponse and Secondary Clinical Nonresponse to Infliximab in Pediatric Crohn’s Disease Patients

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-613-S-613

2019

Volltextzugriff (PDF)

513 DISPARITIES IN OSTOMY CREATION FOR PERIANAL FISTULIZING COMPLICATIONS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE WITHIN A MULTI-INSTITUTIONAL COHORT

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1477-S-1477

2023

Volltextzugriff (PDF)

860 ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN'S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-188-S-188

2023

Volltextzugriff (PDF)

728 PLASMA PROTEOMIC RESPONSE SIGNATURE FOR CHILDREN RECEIVING INFLIXIMAB FOR CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-145-S-146

2021

Volltextzugriff (PDF)

Su519 SHOTGUN METAGENOMICS IDENTIFIES MICROBIAL SIGNATURE CHANGES ASSOCIATED WITH INDUCTION INFLIXIMAB CLEARANCE IN CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-723-S-724

2021

Volltextzugriff (PDF)

613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-130-S-131

2020

Volltextzugriff (PDF)

1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-233-S-234

2020

Volltextzugriff (PDF)

727 ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY)

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-145-S-145

2021

Volltextzugriff (PDF)

303 – Effect of a Practice-Wide Anti-TNF Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-60-S-60

2019

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(266)
Mit Volltextzugriff
(205)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Review article: applying pharmacokinetics to optimise dosing of anti‐TNF biologics in acute severe ulcerative colitis

iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

Uniaxial Compression Tests of Metallic Foams: A Recipe

347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS

748 EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE

Tu1653: MODEL-INFORMED PRECISION DOSING WITH A PK DASHBOARD IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB

Su1884 ACUTE PANCREATITIS IS ASSOCIATED WITH GUT DYSBIOSIS IN CHILDREN

Su1013 EVALUATION OF INSURANCE TYPE ON PRIOR AUTHORIZATION (PA) DELAYS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS PRESCRIBED BIOLOGIC THERAPIES

Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD

DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease

958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE

Su1585: BIOMARKERS OF DRUG CLEARANCE IN PEDIATRIC IBD – A REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY

525: EVALUATION OF HEALTH INEQUITIES IN PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE

Sa1762 – Large-Scale Proteomics Identifies Anti-TNF Response Signature

Su1800 – Effect of Addition of an Immunomodulator on Outcomes in Pediatric Patients with Inflammatory Bowel Disease on Antitnf Monotherapy with New Anti-Drug Antibodies

Su1792 – Elevation of Plasma Oncostatin M is Associated with Primary Biochemical Nonresponse and Secondary Clinical Nonresponse to Infliximab in Pediatric Crohn’s Disease Patients

513 DISPARITIES IN OSTOMY CREATION FOR PERIANAL FISTULIZING COMPLICATIONS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE WITHIN A MULTI-INSTITUTIONAL COHORT

860 ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN'S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP

728 PLASMA PROTEOMIC RESPONSE SIGNATURE FOR CHILDREN RECEIVING INFLIXIMAB FOR CROHN'S DISEASE

Su519 SHOTGUN METAGENOMICS IDENTIFIES MICROBIAL SIGNATURE CHANGES ASSOCIATED WITH INDUCTION INFLIXIMAB CLEARANCE IN CROHN'S DISEASE

613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE

1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE

727 ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY)

303 – Effect of a Practice-Wide Anti-TNF Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Suchergebnisse filtern